LONDON - Shionogi & Co., Ltd. (TYO:4507) has reported positive outcomes from its Phase 2a human challenge trial for an investigational oral antiviral candidate targeting Respiratory Syncytial Virus ...
The EC has authorised the use of ViiV Healthcare’s Vocabria plus Rekambys from J&J for treating adolescents with HIV-1.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback